Mental Health Client-Level Data (MH-CLD) 2021: Data on Clients Receiving Mental Health Treatment Services Through State Mental Health Agencies annual report presents the total number of clients receiving mental health treatment services in 2021 by demographics, National Outcome Measures (NOMs), and the top five mental health diagnoses for children (ages 0-17) and adults (ages 18 and older) by geographic distribution.

The N-SUMHSS is a voluntary annual survey of all active substance use and mental health facilities in the United States, its territories, and D.C. The annual report presents findings on the key operational characteristics of substance use and mental health treatment facilities, use of pharmacotherapies, language assistance services, and suicide prevention assistance services.

An analysis of the 2022 DAWN data presents nationally representative weighted estimates of all drug-related emergency department (ED) visits, nationally representative weighted estimates of the top substances involved in drug-related ED visits, including rates by race and ethnicity; nationally representative weighted estimates of opioid- related ED visits by type of opioid, drugs involved in polysubstance ED visits, and the identification of newly mentioned drugs in 2022.

This tip sheet explores climate change, hot weather, and impacts of heat on people who use medication to manage mental health and other health conditions. It offers steps for individuals and communities to enhance safety and build resilience.

This advisory introduces readers to Cannabidiol (CBD), how it is derived, how it differs from THC and other cannabinoids, the risks and harms of CBD use, and common misconceptions given its broad availability.

The N‑SUMHSS is a voluntary annual survey of all active substance use and mental health facilities in the United States, its territories, and D.C. The annual report presents findings on the general profile of substance use and mental health facilities, use of pharmacotherapies/medications, language assistance provided, and suicide prevention services.

An analysis of final 2021 DAWN data presents: (1) nationally representative weighted estimates, including percent and unadjusted rates per 100,000, for all drug-related emergency department (ED) visits, (2) nationally representative weighted estimates for the top five drugs in drug-related ED visits, (3) the assessment of monthly trends and drugs involved in polysubstance ED visits in a subset of sentinel hospitals, and (4) the identification of drugs new to DAWN’s Drug Reference Vocabulary.